Ppt on anticancer therapy

Diego A. Gomez-Gualdron Midterm Project Nanotechnology; CHEN

apart from bulk solids, with potential applications in medicine. Potential applications DRUG DELIVERY MEDICAL IMAGING DIAGNOSIS & SENSING THERAPY Interesting facts about nanomedicine A. Interest in the area has grown exponentially B. Drug delivery is the most / Eng. 2007. Vol. 9, pp. 257–88 A commercial Anticancer Nanoparticle A. The nanoparticle drug ABRAXANE is one of the fruits of nanomedicine applied to cancer therapy. It consist in nanoparticles carrying an agent interfering with the feeding mechanism/


Anticancer evaluation of some medicinal plants from the Carpathian region Octavian Tudorel Olaru 1, Maryna Van de Venter 2, Trevor Koekemoer 2, Luanne.

Anticancer evaluation of some medicinal plants from the Carpathian region Octavian Tudorel Olaru 1, Maryna Van de Venter 2, Trevor Koekemoer 2, Luanne Venables 2, George Mihai Niţulescu 1 1 “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania 2 “Nelson Mandela” Metropolitan University, Port Elizabeth, South Africa Objectives Although cancer therapy/ showed to have the highest cytotoxicity and can represent promising anticancer sources. However, further studies of the active extracts are /


Monoclonal antibodies Anticancer therapy Weihua Wu.

Monoclonal antibodies Anticancer therapy Weihua Wu What is an antibody? An antibody is a protein used by the immune system to identify and neutralize /and medicine.antibodiesimmune cellclonesbiochemistry molecular biologymedicine The IgG Class of Antibodies  All current therapeutic antibodies are of the IgG class.  When the objective of antibody therapy is to directly kill the target cell, the isotype of choice is IgG1, since this isotype is optimal for complement fixation. The structure of antibodies  /


Cancer Cell Culturing and Cytotoxicity Assays for Anticancer Screening at City of Hope CSULA-COH Cancer Collaborative Presented by: Anthony Martinez.

agents and tumor defense display some similarities Antimicrobial lipids produced naturally in body fluids might exert some anticancer activity Collaborative Design Dr. Porter’s Lab Characterize host- derived lipids with antimicrobial activity University of Wisconsin/: A Manual of Basic Technique, 5th ed. Hoboken, NJ, John Wiley & Sons. Kane, S. (2006). Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents 2: 147-164. Langdon, S/


Optimization of personalized therapies for anticancer treatment Alexei Vazquez The Cancer Institute of New Jersey.

Optimization of personalized therapies for anticancer treatment Alexei Vazquez The Cancer Institute of New Jersey Human cancers are heterogeneous Meric-Bernstam, F. & Mills, G. B. (2012) Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.127 Beltran H et al (2012) Cancer Res DNA-sequencing of aggressive prostate cancers Human cancers are heterogeneous Personalized cancer therapy Meric-Bernstam F & Mills GB (2012) Nat Rev/


Metallopharmaceuticals as Photoactivatable Anticancer Drugs Samar Moqadasi 1,2, Christine O’Connor 1,2, Denis O’Shea 2,3 and Michael Devereux 2,3. 1 School.

Target-based research (treating infected site only), directed towards the design and mechanism of action of metal-based anticancer complexes is expanding rapidly due to the selectivity and activity of such novel therapeutics. The photo activation of Ruthenium/ complexes have been investigated as photosensitising agents for years and it is hoped to apply this property in photodynamic therapy (PDT). The Ru (II) polypyridyl complex will act as a photosensitiser for possible chemotherapeutic effects. The free/


Anticancer drugs: chemotherapy. Hormonal treatment  Hormone-receptor positive (hormone dependent) forms of breast, prostate and ovarian cancer are subject.

Anticancer drugs: chemotherapy Hormonal treatment  Hormone-receptor positive (hormone dependent) forms of breast, prostate and ovarian cancer are subject /) on the receptor for androgens. Inhibition of the synthesis of 5  -dihydrotestosterone by 5-  reductase inhibitors Hormonal treatments: additive hormonal treatments  Additive therapy with high doses of synthetic estrogens (diethylstilbestrol, ethinylestradiol) supresses LH and sex hormones  It is no longer used in prostate and breast cancer due to /


Nanotechnology for Therapy

FDA for treatment of ovarian cancer and multiple myeloma and an AIDS-related cancer. Example of an Approved Anticancer Agent Protein-bound paclitaxel is an injectable formulation of paclitaxel, a mitotic inhibitor drug used in the /AuNPs for NIRF/CT dual imaging, and (C) schematic illustration of PEGylated DoxAuNP@CaP for theranosis. Ultrasound Mediated Therapy Subcutaneously implanted rat prostate carcinomas seven minutes after administration of unspecific microbubbles (L) and RGD-coated microbubbles (R/


Monoclonal antibodies Anticancer therapy Weihua Wu.

Monoclonal antibodies Anticancer therapy Weihua Wu What is antibodies An antibody is a protein used by the immune system to identify and neutralize foreign /their Fab regions both to target antigen and to a conjugate or effector cellbispecific mAbs treatment for cancer cells ADEPT, antibody directed enzyme prodrug therapy; ADCC, antibody dependent cell-mediated cytotoxicity; CDC, complement dependent cytotoxicity; MAb, monoclonal antibody; scFv, single-chain Fv fragment. Carter P: Improving the efficacy/


Hormones & Hormone Antagonists Chapter 40 - Katzung

Hormones & Hormone Antagonists Chapter 40 - Katzung Least toxic of anticancer drugs Highly selective Breast, endometrial, prostate cancers 5 Categories Androgens – Progestins Antiandrogens Gonadotropin-releasing hormone analogs Estrogens – Antiestrogens Aromatase inhibitors Hormone Synthesis Progesterone Aromatase Aromatase Androgens – Breast cancer Indications: palliative therapy in advanced disseminated breast cancer MOA: irreversible inhibitor of the enzyme steroid aromatase that is responsible for the /


Monoclonal antibodies Anticancer therapy. THE IMMUNE SYSTEM DEFINITION: - The integrated body system of organs, tissues, cells & cell products that differentiates.

Monoclonal antibodies Anticancer therapy THE IMMUNE SYSTEM DEFINITION: - The integrated body system of organs, tissues, cells & cell products that differentiates self from non – / regions both to target antigen and to a conjugate or effector cellbispecific mAbs treatment for cancer cells ADEPT, antibody directed enzyme prodrug therapy; ADCC, antibody dependent cell-mediated cytotoxicity; CDC, complement dependent cytotoxicity; MAb, monoclonal antibody; scFv, single-chain Fv fragment. Carter P: Improving/


Monoclonal antibodies Anticancer therapy. Lymphocytes Produce antibodies B-cells mature in bone marrow then concentrate in lymph nodes and spleen T-cells.

Monoclonal antibodies Anticancer therapy Lymphocytes Produce antibodies B-cells mature in bone marrow then concentrate in lymph nodes and spleen T-cells mature in/their Fab regions both to target antigen and to a conjugate or effector cellbispecific mAbs treatment for cancer cells ADEPT, antibody directed enzyme prodrug therapy; ADCC, antibody dependent cell-mediated cytotoxicity; CDC, complement dependent cytotoxicity; MAb, monoclonal antibody; scFv, single-chain Fv fragment. Carter P: Improving the efficacy/


Anticancer Therapy: Kinase Inhibitors Charles Harrell.

Anticancer Therapy: Kinase Inhibitors Charles Harrell Outline of Material Presented Definition of Cancer Understanding Kinases Kinase Inhibitor Functionality /of human malignancies, mutations that constitutively activate protein tyrosine kinases are implicated in malignant transformation; thus protein tyrosine kinases are targets for cancer therapy.” Oncogenic Transformation http://www.youtube.com/watch?v=3nODx3cT1RU Can occur in a number of different ways Important distinction is that the kinase remains/


1 ANTICANCER DRUGS & IMMUNOMODULATORS. 2 “CANCER” Refers to a Malignant neoplasm (New growth) Cancer cells can manifest: Uncontrolled Proliferation. Loss.

1 ANTICANCER DRUGS & IMMUNOMODULATORS 2 “CANCER” Refers to a Malignant neoplasm (New growth) Cancer cells can manifest: Uncontrolled Proliferation. Loss of/and in treatment of both hodgkins and nonhodgkins lymphoma. Adv effects- cataracts, glaucoma, hyperglycemia, osteoporosis, mood swings 53 Tamoxifen SERM Estrogen antagonist First line therapy for estrogen receptor positive breast cancer Binds to estrogen receptors Leading to Depletion of estrogen receptors Not related to any specific cell phase. SE : hot /


Welcome to St Clare Hospice. l Welcome l Pain control: getting it right l Hospice in-patient care l Hospice Day Therapy l Hospital Palliative Care l Community.

Therapy l Hospital Palliative Care l Community Palliative Care l Case Studies l Close Outline Pain control: getting it right john.zeppetella@stclarehospice.org.uk 53% all stages of disease 53% all stages of disease 59% of patients on active anticancer treatment 59% of patients on active anticancer /Clinicians Clinicians Patients Patients Health care system Health care system Barriers Managing cancer pain Hormone therapy Analgesics Chemotherapy Surgery Radiotherapy Anaesthetic procedures Adjuvant analgesics


ANTICANCER AND ANTI-HIV DRUGS DERIVED FROM AFRICAN AND OTHER PLANTS

4 billion people utilize plants to meet their primary health care needs *Farnsworth NR, et al. Medicinal Plants in Therapy. Bull. W.H.O. 63:965-981 (1985) PLANT-DERIVED DRUGS Analgesics: Aspirin: Salix species/Europe Morphine/ by Electron Crystallography" Science, 6 August 2004, Vol. 305, pp. 866-869 (Copyright AAAS) PLANT-DERIVED ANTICANCER DRUGS IN CLINICAL USE OR DEVELOPMENT Vinblastine/Vincristine: Catharanthus roseus/Jamaica, Philippines (originally from Madagascar) Etoposide: Podophyllum species/


CANCER CHEMOTHERAPY. General Principles of Action of Anticancer Drugs A. Treatment strategies B. Treatment regimens and scheduling C. Problems associated.

CANCER CHEMOTHERAPY General Principles of Action of Anticancer Drugs A. Treatment strategies B. Treatment regimens and scheduling C. Problems associated with chemotherapy A. Treatment /Antibodies Trastuzumab Trastuzumab (Herceptin®) is a humanized monoclonal antibody that acts on the HER2/neu (erbB2) receptor. Its principal use is as an anticancer therapy in breast cancer patients whose tumors overexpress this receptor. It is administered either once a week or once every three weeks IV. Rituximab Rituximab /


Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.

Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI CONFIDENTIAL /other subtypes.  Autophagy has a cytoprotective function that enables cancer cells to cope with cytotoxic or other stresses induced by treatment. Thus, anticancer therapies commonly lead to the upregulation of autophagy. FDA-approved chloroquine or hydroxychloroquine in combination with chemo- or radiotherapy for the treatment of different /


VR-23, a New Anticancer Drug Developed in Northern Ontario Hai-Yen Vu, PhD and Hoyun Lee, PhD.

products/compounds 4.Drug discovery project II Anti-bacterial Anti-fungal Anti-parasitic Drug Discovery Project I Focus: Developing effective and safe anticancer drugs (as single regimens or in combinations with other drugs) Cinchona (Quina) Yew tree Willow & Spiraea  Inhibitors of signal/VR23’s efficacy on other cancer types  Developing effective combinational therapies utilizing biomarkers being studied in our lab Next Steps NSERC Acknowledgement NOHFC V. Raja Solomon Sheetal Pundir Funders: Researchers:


Erythropoietin Preserves the Endothelial Differentiation Capacity of Cardiac Progenitor Cells and Reduces Heart Failure during Anticancer Therapies Melanie.

Erythropoietin Preserves the Endothelial Differentiation Capacity of Cardiac Progenitor Cells and Reduces Heart Failure during Anticancer Therapies Melanie Hoch, Philipp Fischer, Britta Stapel, Ewa Missol-Kolka, Belaid Sekkali, Michaela Scherr, Fabrice Favret, Thomas Braun, Matthias Eder, Karin Schuster-Gossler, Achim Gossler, Andres Hilfiker, Jean-Luc Balligand, Helmut /


© Oxford University Press, 2013 ANTICANCER AGENTS PROTEIN KINASE INHIBITORS Patrick: An Introduction to Medicinal Chemistry 5e Chapter 21.

© Oxford University Press, 2013 ANTICANCER AGENTS PROTEIN KINASE INHIBITORS Patrick: An Introduction to Medicinal Chemistry 5e Chapter 21 © Oxford University /tumours Drug resistance unlikely to occur for all kinase targetsDrug resistance unlikely to occur for all kinase targets Equivalent of combination therapy (poly-pharmacology)Equivalent of combination therapy (poly-pharmacology) Sometimes called ‘promiscuous drugs’Sometimes called ‘promiscuous drugs’ Promising agents against tumours that are driven by /


Highlights in the Managment of Urogenital Cancer Future directions for targeted therapies in advanced renal cell cancer Alessandro Morabito Unità Sperimentazioni.

be presented at ASCO 2008 Placebo + BSC N=362 2 : 1 RAD001 : Placebo NCT00410124. www.clinicaltrials.gov PatientsSetting Therapy (level 1) Options (level  2) Naive MSK Risk: good or intermediate Sunitinib (Bevacizumab + IFN) HD IL-2/cytoreductive nephrectomy –ECOG performance status less than or equal to 1 –patients must not have received any systemic anticancer therapy Radiation therapy is allowed if >/= 2 weeks from study drug administration NCT00113217. www.clinicaltrials.gov. Start Date: February 2005/


Breast Cancer Management. How treatment is planned The main treatments for breast cancer are Surgery Radiotherapy Hormone therapy Chemotherapy Biological.

ovaries to make and release oestrogen. The commonest of these drugs is goserelin (Zoladex) Biological therapy Monoclonal antibody therapy is a cancer treatment that uses antibodies made in the laboratory These antibodies can identify substances /kinase inhibitors as adjuvant therapy Tyrosine kinase inhibitors are targeted therapy drugs that block signals needed for tumors to grow. Tyrosine kinase inhibitors may be used in combination with other anticancer drugs as adjuvant therapy. Tyrosine kinase inhibitors/


Clinical case for ions Reinhard Schulte, MD,MS, DABR Professor, Radiation Research Loma Linda University Principal Investigator Particle Therapy Research.

meta-analyses, this is on top of additional improvement in control and survival from chemotherapy, hormone therapy, and targeted therapy (HER2-directed) The statistically proven survival advantages do not show earlier than 10-15 years and / weeks and treating patients with locally advanced pancreatic cancer followed by an ongoing clinical trial of CIRT combined with anticancer drug gemcitabine starting in 2005 Twenty-three (23) patients underwent preoperative CIRT between April 2003 through February 2010./


FACET - European Journal of Cancer Care September 2006 slides available at: www.blackwellpublishing.com/ecc Oral anti-cancer therapies Oakley, C. 1, Bloomfield,

on View; Notes Page for explanatory notes slides available at: www.blackwellpublishing.com/ecc Oral anti-cancer therapies (continued) Workshop outcomes Transforming delivery – identified barriers key issues potential resources Who, where, when Pathway / Pharmacists Association (BOPA) (2004) Position Statement on Safe Practice and the Pharmaceutical Care of Patients Receiving Oral Anticancer Chemotherapy. January 2004. BOPA, UK. FACET - European Journal of Cancer Care September 2006 Slide Twenty Seven /


A Case Based Approach to Hormone Therapy Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller.

CIA* on AIs (16 upfront, 20 switching, 9 extended) Median age: 47 (range 39-52) 33 biochemically confirmed ovarian suppression before therapy 12 (27%) recovered ovarian function –menses [10], –pregnancy without menses [1], –biochemical assay without menses [1] Median duration of amenorrhea/ 0.06 0.08 0.10 0.12 0.14 012345 Time since randomization (years) Cumulative Rate Jassem, J. et al Anticancer Drugs. 2008 Feb;19 Suppl 1:S3-7. IES - Intergroup Exemestane Study Consistency of OS Across Subgroups 0.84 (0.61/


Recognition and Management of Nonmelanoma Skin Cancer in Solid Organ Transplant Recipients and Other High-Risk Populations: Advances in Oral Retinoid Therapy.

treatment of warts and AKs –Premalignant lesions –Destructive modalities (cryosurgery, ED&C, PDT, laser ablation, chemical peels) or topical therapy (5-FU, diclofenac, imiquimod) –Possible topical chemoprevention Surgery –Standard treatment, effective with relatively low morbidity in low-risk populations, /1988;318:1633-1637.Levine N et al. Cancer Epidemiol Biomarkers Prev. 1997;6:957-961. Somos S et al. Anticancer Res. 1999;19:2195-2199. Tangrea JA et al. J Natl Cancer Inst. 1992;84:328-332. Bellman BA /


WEB&Z 8 december 2015 Huiswerk Physical therapy interventions for children and adolescents during and following treatment of cancer Edith Leclercq Trials.

education, and electrophysical modalities for symptom relief. Comparison:control, standard care, alternate intervention assuming the effect of the physical therapy intervention can be isolated. Outcome:Primary: Quality of life Secondary: pain, fatigue, function, gait, balance, range / Agents "[mh] OR (cancer therap*[tiab] OR cancer treat*[tiab] OR chemotherap*[tiab] OR antineoplas*[tiab] OR anticancer*[tiab] OR anti neoplas*[tiab] OR anti cancer*[tiab])) AND (child[mh] OR infant[mh]OR adolescent[mh]/


Novel Biologic Therapies for Second-Line Gastric Cancer

Cancer Res. 2009;15:1821-29; 4Taguchi F et al. Invest New Drugs. 2011;29:1198-205; 5Cejka D et al. Anticancer Res. 2008;28:3901-08; 6Jaeger-Lansky A et al. Cancer Biol Ther. 2010;9:919-27; 7Doi T et al. / 1st line platinum/fluoropyrimidine based chemotherapy Stratification factors: - Geographic region, - Measurable vs non-measurable disease, - Time to progression on 1st line therapy (< 6 mos vs. ≥ 6 mos) * GEJ= gastroesophageal junction; gastric and GEJ will be summarized under the term GC ToGA: A Randomized/


Sponsored By:. SABCS 2011 Review: HER2-Directed Therapy in Breast Cancer Chau Dang, MD Assistant Professor of Medicine Weill Cornell Medical College Breast.

measurable lesion), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) San Antonio Breast Cancer Symposium – Cancer Therapy and Research Center at UT Health Science Center – December 6–10, 2011 This presentation is the intellectual property of / or early-stage breast cancer Primary tumor ≥2 cm Baseline LVEF ≥55% ECOG PS 0 or 1 No previous anticancer therapy or radiotherapy for any malignancy Adequate bone marrow, liver, and renal function Schneeweiss abs #S5-6 Baseline Characteristics FEC//


Herceptin ® Targeted Therapy for HER2 Positive Breast Cancer Prof B.Klein Head of Oncology Hasharon hospital.

poor prognosis and shortened disease-free/overall survival HER2 receptor provides an extracellular target for novel and specific anticancer treatment (monoclonal antibodies) Transmembrane structure of HER2 monomer Extracellular domain (632 amino acids) Ligand-binding site/ improves DFS and DDFS (HERA) Concurrent chemotherapy plus trastuzumab may be superior to sequential therapy (N9831) Concurrent therapy a la N9831 associated with greater cardiotoxicity Disease-Free Survival: Control vs Sequential 100 90/


Biology of Cancer Principles of Systemic Therapy.

–oral or intravenous –bolus or continuous infusion Specific toxicities: –nonoverlapping/overlapping –facilitate combination chemotherapy Targeted Therapies Round 6 Receptors HER-2 proteins Antiangiogenesis Treatment Options for Women with HER2 Positive Breast Cancer “The /: relapse (p=0.001) overall survival (p=0.02)  The HER2 receptor provides:  Extracellular target specific anticancer treatment  Herceptin Slamon DJ et al. Science 1987;235:177–82 Indicators of Increased HER2 Production 1 =  gene/


89-SrCl2 Serum Concentrations of IL-2 and TNF- a in Patients with Painful Bone Metastases: Correlation with Responses to 89-SrCl2 Therapy THE JOURNAL OF.

these mechanisms, it plays an important role in anti-tumor immune responses. TNF-a TNF-a, another important cytokine in anticancer therapy, is produced primarily by mononuclear macrophages. TNF-a can initiate an intensive immunoinflammation response, induce natural killer cells and /levels of IL-2 and TNF-a were significant in responders but not in nonresponders. summary 89-SrCl 2 therapy improves levels of measured cytokines, presumably by killing bone metastases. The combination of TNF-a and IL-2 /


IMMUNOSUPPRESSANT DRUGS AND GENE THERAPY Dr. Rishi Pal Assist. Professor Department of Pharmacology.

to DNA. –Prodrug, activated into phosphamide. –Is given orally& intravenously –Destroy proliferating lymphoid cells. –Anticancer & immunosuppressant –Effective in autoimmune diseases e.g rheumatoid arthritis & systemic lupus erythrematosus. –Autoimmune hemolytic anemia Side/ "position effect"), and thus the gene regulatory aspects are always uncertain after gene therapy Successful Gene Therapy for Severe Combine Immunodeficiency Infants with severe combined immunodeficiency are unable to mount an adaptive/


Recognition and Management of Nonmelanoma Skin Cancer in Solid Organ Transplant Recipients: Advances in Oral Retinoid Therapy.

liver function test. Kraemer KH et al. N Engl J Med. 1988;318:1633-1637. Somos S et al. Anticancer Res. 1999;19:2195-2199. Bellman BA et al. Transplantation. 1996;61:173. Levine N et al. Cancer/2004. 2. Accutane ® (isotretinoin capsules) prescribing information. Nutley, NJ: Roche Laboratories Inc; June 2002. 63 Managing Oral Retinoid Therapy Gradual dose escalation Routine laboratory monitoring –Pregnancy testing in women of reproductive potential –Lipids –LFTs Preventive AE management –Early toxicity may be/


Targeted therapy: Falso mito o reale innovazione? Stefano Iacobelli Cancer Clinic & Laboratory of Molecular Oncology Consorzio Interuniversitario Nazionale.

cells, stimulate the immune system to destroy specific cancer cells, and deliver toxic drugs to cancer cells. What are Targeted Therapies? NCI www.cancer.gov Langer C & Soria JC, Clin Lung Cancer 11: 82-90, 2010 Mechanisms of common Targeted Anticancer Therapies: mAbs and TKIs a Agents with antiangiogenic mechanism Li J et al., Targ Oncol 2012 FDA approved TKIs and mAbs for/


Genomics, personalized medicine

case childhood leukemia, often respond differently to a drug treatment because of subtle differences in gene expression. The dose of an anticancer drug (6-MP) that works for one person may be toxic for another person. Several methods are being developed for/that Gleevec was effective against CML, with minimal side effects and a higher remission rate than that seen with conventional therapies. Gleevec is now used to treat CML and several other cancers. With scientists discovering more genes and gene products /


Dr. Mahmoud H. Taleb 1 Lecture 10: Antifungal therapy.

often occur in tissues that are poorly penetrated by antimicrobial agents (e.g., devitalized or avascular tissues). -Therapy of fungal infections usually requires prolonged treatment. -Advances in medical technology, including organ and bone marrow transplantation, /areas of pharmacologic investigation. Research in antiviral chemotherapy began in the early 1950s, when the search for anticancer drugs generated several new compounds capable of inhibiting viral DNA synthesis. Dr. Mahmoud H. Taleb48 Recent /


Liver directed therapy – when and how? V. Heinemann Department of Oncology and Comprehensive Cancer Center University of Munich, Germany.

liver remnant YesNo resection Metastases nearby biliary ducts/vessels Yes SRx No RFA Van der Pool AEM J Gastrointest Surg 2009 Intraarterial Hepatic Therapy Options  hepatic arterial infusion (HAI)  drug-eluting beads (DEB-TACE)  radioembolization (SIRT) Contraindications  poor liver function/intervals FOLFIRI:8 courses iv at 2-wk intervals Fiorentini G, et al. ESMO 2010; #588 see also Anticancer Res 2012 Radioembolization (SIRT) Yttrium-90 labelled microspheres –mean diameter 32 µm –beta 0.93 MeV –half /


Targeted Therapy beim Rektumkarzinom - moderne Strategien der systemischen Therapie Dr. Irene Kührer MUW, Wien.

AM. Patholog Res Int. 2011;2011:932932; Sitohy B, et al. Cancer Res 2012;72:1909-1914; Bendardaf R, et al. Anticancer Res. 2008;28:3865-3870; Kitadai Y, et al. Am J Pathol. 2006;169:2054-2065; Jayson GC, et al. J /mutant BRAF; Selutmetinib and pimasertib targeting MEK; LY294002 and GDC0941 are targeting P13K Conclusion: Where we are at in Cancer Therapies? Adjuvant therapy in colorectal cancer The last 30 years have only seen small but progressive improvement in survival for patients with colorectal cancer/


Targeted therapies in Gastroesophageal Malignancies Dawn of a new era Manish A. Shah, MD Associate Professor of Medicine Weill Cornell Medical College.

0-9%) of esophageal cancers Mukaida. Cancer 1991; Itakura. Cancer 1994; Yacoub. Mod Pathol 1997; Torzewski. Anticancer Res 1997; Koyama. J Cancer Res Clin Oncol 1999; Lea. Carcinogenesis 2006 Abstract LBA6 - Background RTOG 0436 /fluoropyrimidine based chemotherapy Stratification factors: - Geographic region, - Measurable vs non-measurable disease, - Time to progression on 1st line therapy (< 6 mos vs. ≥ 6 mos) Important inclusion criteria: - Metastatic or loc. adv. unresectable gastric or GEJ* /


PROSPECTIVE ANALYSIS OF DENDRITIC CELL(DC)THERAPY IN CANCER PATIENTS Kananathan.R*,Khan Jamal** *NCI Hospital,Nilai Negeri Sembilan, Malaysia **Institute.

months, and during this period it is able to selectively transform trillions of T cells. The robust anticancer immunology doesn’t allow new malignant cells to grow and effectively stops or delays tumor progression. Dendritic/ CHEMORADIOTHERAPY 6CYCLES OF PACLITAXEL AND CARBOPLATIN 2 HARVESTING36MONTHS 17MONTHS POST RECURRENCE YCCFEMALECA CHOLONGIO CARCINOMA IVNIL3LINES OF THERAPY HIFU SIRTEX AIET 2 HARVESTING30MONTHS AR36FEMALECA LEFT BREAST TRIPLE NEGATIVE IIIC1 LEFT MASTECTOMY WITH AXILLARY CLEARENCE /


“Cancer2006: From molecular biology processes to tumor-tailored therapy” 20-24, august, 2006 High Tatras, Slovakia THE INVITED SPEAKERS – BRIEF SCIENTIFIC.

the organophosphorus insecticide malathion and its two analogues. Mutat Res. 1999 PUBLICATIONS: Session 9: TUMOR-TAILORED THERAPIES Geoffrey Margison, PhD Paterson Institute for Cancer Research senior investigator Manchester, United Kingdom Title of the lecture:/-resistant cell lines. Anticancer Res. 2005 PUBLICATIONS: Session 9: TUMOR-TAILORED THERAPIES Prof. Martin Brendel Universidade Estadual de Santa Cruz, Bahia, Brasil Title of the lecture: Tumor regression by antisense therapy against Plk1 and Bcl/


Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.

treatment to follow MTX Cleaves leucovorin –Allow 2-4 hour interval between medications –Current investigation –Continue therapy for 48 hours after glucarpidase Availability: HD/HP while awaiting Schwartz S et al.Oncologist 2007; 12/Vinca alkaloidsVincristine, vinblastine TaxanePaclitaxel Non-classical alkylatorAmsacrine Goolsby 2006, Schrijvers 2003, Wang 2006 Doxcetaxel El Saghir NS. Anticancer Drugs 2004;15:401-404. Not for publication. For educational use only. Non-DNA Binding Vesicants Vinblastine /


Anti-angiogenic therapy: a new approach to the treatment of metastatic breast cancer Kathy Miller Indiana University School of Medicine, USA.

(Vascularised tumor) (Tumor cell intravasation) (Seeding in distant organs) (Secondary angiogenesis) VEGF: a candidate for anticancer therapy Tumors rely on their existing vasculature for survival VEGF is a powerful survival factor for the immature vessels that comprise/ tumor microvasculature 1 The abnormal structure and function of tumor vasculature inhibits the action of conventional therapies 2 inhibition of VEGF normalizes existing vasculature 3 Tumors require new vasculature for growth and metastasis /


Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

is the target for several new anticancer therapies EGFR-targeted therapy cell surface portion binds epidermal growth factor intracellular tyrosine kinase transmit signal by phosphorylation CELL MEMBRANE EGFR-targeted therapy Small molecule inhibitors Therapeutic antibody: Cetuximab/processing in cancer cells –Effects of mutations and abnormal gene expression –Discovery of new targets for therapy: key modulators of pathway function –Effects of therapeutic inhibitors –Possible side effects Effects of abnormal/


THERAPEUTIC MODALITIES  LOCAL TREATMENTS  SURGERY  RADIATION THERAPY  SYSTEMIC TREATMENTS  CHEMOTHERAPY  BIOLOGIC THERAPY.

control factors in cancer. (Biologic response modifiers stimulate selected immune cells, which then demonstrate anticancer activity [interferons, ILs, and GFs.] Exploitation of maturation abnormalities. Maturation factors ( Transretinoic acid/ chemotherapy should be postponed until symptoms require palliation Timing of Chemotherapy A) Induction chemotherapy (initial therapy to achieve significant cytoreduction (complete remission) of disease. B)Consolidation/Intensification chemotherapy (postremission, same/


Therapies targeting the immune system:  Stimulation  Suppression  Modulation.

Antiinflammatory effect Nature Reviews Cancer 2; 750-763 (2002); doi:10.1038/nrc903 LIGAND-TARGETED THERAPEUTICS IN ANTICANCER THERAPY < previous next > Antibodies and antibody fragments Bio-similar, bio-better, me-better Biosimilar antibodies are “/ shock (100 000/year) –sepsis Kawasaki disease: chronic vasculitis - IVIG – neutralization effect, IVIG therapy - examples Intravenous Ig therapy, (IVIG) Immunmodulatory, anti-inflammatory effect α2,6 SA containing IVIG antiinflammatory effect - model α2/


Controversies in Neoadjuvant Therapy for Esophageal / GEJ Carcinoma

2 most common approaches: Neoadjuvant chemo  surgery (+ post-op chemo) Neoadjuvant chemoradiation  surgery Rationale for Neoadjuvant Therapy Treat micrometastatic disease Downstage tumor, increase probability of curative resection Decrease tumor cell dissemination during resection Patients more likely/ post Esophageal Cancer Resection (%) Locoregional Hematogenous / distant Mixed Osugi Oncol Rep 2003 11 58 - Kato Anticancer Rsrch 2005 22 51 27 Fahn ATS 1994 33 61 Abate JACS 2010 30 60 10 Bottom line for/


BIOM 255: Molecular basis of drug action and disease therapy BLOCK 1: General principles of pharmacology Block Leader: Paul Insel 1. Jan 10: Paul Insel:

.g., genetics, age, gender, co-existing disease) Selective toxicity for drugs used as chemotherapeutic (antimicrobial, anticancer) agents or pesticides (e.g.,insecticides) that kill targets without harming the host Difficult to achieve selective /formulations with an increased number of “biological drugs” (e.g., antibodies, binding proteins, ?antisense, ?siRNA, ?gene therapy) –Alternative methods of drug delivery (less pain and other side effects, better/more consistent delivery and bioavailability) –Less-/


Ads by Google